CMV-Specific CAR-T Cells for Targeting Infected Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cytomegalovirus (CMV) infections, particularly in immunocompromised individuals, are limited, with autologous immunotherapy using expanded CMV-specific CD8+ T lymphocytes being technically challenging and gene therapy with a chimeric antigen receptor (CAR) against CMV not having advanced to clinical trials.
Innovation Solution
Development of CMV-specific chimeric antigen receptors (CARs) comprising specific single-chain antibody sequences, which are expressed in CD8+ T lymphocytes to target and eliminate CMV-infected cells, utilizing expression vectors to deliver these CARs to host cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous immunotherapy using expanded CMV-specific C8TLs is used, then treatment efficacy is improved, but technical limitations and complexity increase
Solution Approach 1:
The patent creates CAR-T cells that copy the desired CMV-specific cytotoxic function without requiring complex autologous expansion processes. The chimeric antigen receptor provides a standardized, replicable solution that bypasses the technical limitations of traditional adoptive T-cell therapy while maintaining treatment efficacy.
Solution Approach 2:
The invention changes the fundamental parameter of T-cell activation from antigen-specific TCR recognition to CAR-mediated antigen recognition. This parameter change simplifies the therapeutic approach by enabling direct targeting of CMV-infected cells through the CAR construct, eliminating the need for complex ex vivo expansion and selection processes.
2Loss of time
If only one reported CMV-specific CAR is used, then development time is reduced, but clinical applicability is limited
Solution Approach 1:
The patent develops multiple CMV-specific CARs with different antigen targets (gB, gH, gL, pentameric complex) to create a universal therapeutic platform. This multi-target approach ensures broad clinical applicability across different CMV strains and infection scenarios, overcoming the limitations of relying on a single CAR design.
Solution Approach 2:
The invention segments the CMV antigen targets into multiple distinct CAR designs, each targeting specific viral proteins. This segmentation allows for diversified clinical applications and enables selection of the most effective CAR based on the specific infection context, thereby enhancing overall clinical versatility.
3Ease of operation
If existing therapies are used, then treatment simplicity is maintained, but ability to target and eliminate infected cells is insufficient
Solution Approach 1:
The patent introduces CAR-T cells as an intermediary therapeutic agent that bridges the gap between simple administration and effective viral elimination. The CAR construct serves as a mediator that directs T cells to specifically recognize and kill CMV-infected cells, combining operational simplicity with targeted efficacy.
Data Source
AI summary
Disclosed herein are CMV-specific CARs. In some embodiments. the present invention is directed to a method of treating, reducing, or inhibiting an infection by a cytomegalovirus in a subject, which comprises administering to the subject (a) an expression vector that encodes a CMV-specific CAR as described herein, or (b) one or more cells that are transduced with the expression vector.